Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Never miss an Options trading signal: Unusual Options Activity and Options Screeners with Barchart Premier. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or

Larimar Therapeutics Inc (LRMR)

Larimar Therapeutics Inc (LRMR)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
News & Headlines for [[ item.sessionDateDisplayLong ]]
Larimar Therapeutics Presents Promising Data on Nomlabofusp at International Congress for Ataxia Research, Showing Potential to Enhance Frataxin Levels in Friedreich's Ataxia Patients

Nomlabofusp shows potential to improve frataxin levels and lipid profiles in Friedreich’s ataxia patients, with further studies planned.Quiver AI SummaryLarimar Therapeutics presented data on its treatment...

LRMR : 6.00 (-1.32%)
Larimar Therapeutics Presents Additional Data from Phase 1 Studies and Phase 2 Dose Exploration Study Supporting the Nomlabofusp Clinical Program at ICAR 2024

LRMR : 6.00 (-1.32%)
Zacks Industry Outlook Madrigal, Corcept, Catalyst Larimar and Theravance

For Immediate ReleaseChicago, IL – November 11, 2024 – Today, Zacks Equity Research like Madrigal Pharmaceuticals MDGL, Corcept Therapeutics CORT, Catalyst Pharmaceuticals CPRX, Larimar Therapeutics...

CORT : 55.78 (-0.55%)
TBPH : 9.95 (-0.20%)
MDGL : 320.00 (+0.92%)
LRMR : 6.00 (-1.32%)
CPRX : 20.97 (-0.85%)
5 Small Drug Stocks to Buy as Trump Gets Re-Elected

The drug industry witnessed major policy changes during Joe Biden's four-year term as U.S. President, including the historic Inflation Reduction Act (“IRA”). With Donald Trump’s reelection, the biotech...

CORT : 55.78 (-0.55%)
TBPH : 9.95 (-0.20%)
MDGL : 320.00 (+0.92%)
LRMR : 6.00 (-1.32%)
CPRX : 20.97 (-0.85%)
Larimar: Q3 Earnings Snapshot

Larimar: Q3 Earnings Snapshot

LRMR : 6.00 (-1.32%)
Larimar Therapeutics Reports Third Quarter 2024 Operating and Financial Results

LRMR : 6.00 (-1.32%)
Larimar: Q2 Earnings Snapshot

Larimar: Q2 Earnings Snapshot

LRMR : 6.00 (-1.32%)
2 Potentially High-Reward Growth Stocks to Buy Right Now

These two biotechnology stocks could be gearing up for a run.

RNA : 43.01 (-1.47%)
LRMR : 6.00 (-1.32%)
Stock Index Futures Mixed Ahead of More Fed Speak, Nvidia Earnings Awaited

June S&P 500 E-Mini futures (ESM24) are up +0.03%, and June Nasdaq 100 E-Mini futures (NQM24) are down -0.08% this morning as investors awaited further comments from Federal Reserve officials while also...

ESM24 : 5,471.89s (-0.09%)
NQM24 : 19,747.29s (-0.08%)
NCLH : 26.23 (+0.73%)
MU : 98.35 (-0.02%)
NVDA : 141.95 (-2.70%)
JPM : 242.88 (+0.87%)
LOW : 264.04 (+0.38%)
AZO : 3,074.00 (+0.80%)
TOL : 152.73 (+0.54%)
M : 14.74 (+1.24%)
URBN : 36.94 (+0.08%)
SFSN.Z.EB : 123.000 (-0.32%)
Larimar: Q1 Earnings Snapshot

Larimar: Q1 Earnings Snapshot

LRMR : 6.00 (-1.32%)

Barchart Exclusives

Ambarella Earnings Preview: What to Expect from the Semiconductor Stock in Q3
Down almost 80% from all-time highs, Ambarella is a tech stock that trades at a discount to consensus price target estimates. Read more
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.

Free Barchart Webinar